CoChat

Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response

Zhao, Mei, Wang, Tianxiao, Gleber-Netto, Frederico O., Chen, Zhen, McGrail, Daniel J., Gomez, Javier A., Ju, Wutong, Gadhikar, Mayur A., Ma, Wencai, Shen, Li, Wang, Qi, Tang, Ximing, Pathak, Sen, Raso, Maria Gabriela, Burks, Jared K., Lin, Shiaw-Yih, Wang, Jing, Multani, Asha S., Pickering, Curtis R., Chen, Junjie, Myers, Jeffrey N., Zhou, Ge · 2024 · Nature Communications
Cited by 65

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Inactivating TP53 mutations leads to a loss of function of p53, but can also often result in oncogenic gain-of-function (GOF) of mutant p53 (mutp53) proteins which promotes tumor development and progression. The GOF activities of TP53 mutations are well documented, but the mechanisms involved remain poorly understood. Here, we study the mutp53 interactome and find that by targeting minichromosome maintenance complex components (MCMs), GOF mutp53 predisposes cells to replication stress and chromosomal instability (CIN), leading to a tumor cell-autonomous and cyclic GMP–AMP synthase (cGAS)-stimulator of interferon genes (STING)-dependent cytosolic DNA response that activates downstream non-canonical nuclear factor kappa light chain enhancer of activated B cell (NC-NF-κB) signaling. Consequently, GOF mutp53-MCMs-CIN-cytosolic DNA-cGAS-STING-NC-NF-κB signaling promotes tumor cell metastasis and an immunosuppressive tumor microenvironment through antagonizing interferon signaling and regulating genes associated with pro-tumorigenic inflammation. Our findings have important implications for understanding not only the GOF activities of TP53 mutations but also the genome-guardian role of p53 and its inactivation during tumor development and progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-023-44239-2

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Research works printed but not linked: 75

  1. Livingstone, L. R. et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70, 923–935 (1992). · DOI · Paper page
  2. Wahl, G. & Vafa, O. Genetic instability, oncogenes, and the p53 pathway. Cold Spring Harb. Symp. Quant. Biol. 65, 511–520 (2000). · DOI
  3. Kastan, M. B. Wild-type p53: tumors can’t stand it. Cell 128, 837–840 (2007). · DOI
  4. Lane, D. P. Cancer. p53, guardian of the genome. Nature 358, 15–16 (1992). · DOI · Paper page
  5. Feldser, D. M. et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468, 572–575 (2010). · DOI · Paper page
  6. Chunduri, N. K. & Storchova, Z. The diverse consequences of aneuploidy. Nat. Cell. Biol. 21, 54–62 (2019). · DOI · Paper page
  7. Williams, B. R. et al. Aneuploidy affects proliferation and spontaneous immortalization in mammalian cells. Science 322, 703–709 (2008). · DOI · Paper page
  8. Hong, C. et al. cGAS-STING drives the IL-6-dependent survival of chromosomally instable cancers. Nature 607, 366–373 (2022). · DOI · Paper page
  9. Kim, C. et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell 173, 879–893.e813 (2018). · DOI · Paper page
  10. Davoli, T., Uno, H., Wooten, E. C. & Elledge, S. J. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355, eaaf8399 (2017). · DOI · Paper page
  11. Bielski, C. M. et al. Genome doubling shapes the evolution and prognosis of advanced cancers. Nat. Genet. 50, 1189–1195 (2018). · DOI · Paper page
  12. Taylor, A. M. et al. Genomic and functional approaches to understanding cancer aneuploidy. Cancer Cell 33, 676–689.e673 (2018). · DOI · Paper page
  13. Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. Cell 173, 1823 (2018). · DOI · Paper page
  14. Gerstung, M. et al. The evolutionary history of 2,658 cancers. Nature 578, 122–128 (2020). · DOI · Paper page
  15. Oren, M. & Rotter, V. Mutant p53 gain-of-function in cancer. Cold Spring Harb. Perspect. Biol. 2, a001107 (2010). · DOI · Paper page
  16. Mantovani, F., Collavin, L. & Del Sal, G. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 26, 199–212 (2019). · DOI · Paper page
  17. Freed-Pastor, W. A. & Prives, C. Mutant p53: one name, many proteins. Genes Dev. 26, 1268–1286 (2012). · DOI · Paper page
  18. Kim, M. P. & Lozano, G. Mutant p53 partners in crime. Cell Death Differ. 25, 161–168 (2018). · DOI · Paper page
  19. Schulz-Heddergott, R. et al. Therapeutic ablation of gain-of-function mutant p53 in colorectal cancer inhibits stat3-mediated tumor growth and invasion. Cancer Cell 34, 298–314.e297 (2018). · DOI · Paper page
  20. Cooks, T., Harris, C. C. & Oren, M. Caught in the cross fire: p53 in inflammation. Carcinogenesis 35, 1680–1690 (2014). · DOI · Paper page
  21. Pilley, S., Rodriguez, T. A. & Vousden, K. H. Mutant p53 in cell-cell interactions. Genes Dev. 35, 433–448 (2021). · DOI · Paper page
  22. Redman-Rivera, L. N. et al. Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes. Nat. Commun. 12, 5184 (2021). · DOI · Paper page
  23. Simon, N. E. & Schwacha, A. The Mcm2-7 replicative helicase: a promising chemotherapeutic target. Biomed. Res. Int. 2014, 549719 (2014). · DOI
  24. Woodward, A. M. et al. Excess Mcm2-7 license dormant origins of replication that can be used under conditions of replicative stress. J. Cell. Biol. 173, 673–683 (2006). · DOI · Paper page
  25. Ibarra, A., Schwob, E. & Mendez, J. Excess MCM proteins protect human cells from replicative stress by licensing backup origins of replication. Proc. Natl Acad. Sci. USA 105, 8956–8961 (2008). · DOI · Paper page
  26. Das, M., Singh, S., Pradhan, S. & Narayan, G. MCM paradox: abundance of eukaryotic replicative helicases and genomic integrity. Mol. Biol. Int. 2014, 574850 (2014). · DOI
  27. Seo, Y. S. & Kang, Y. H. The human replicative helicase, the CMG complex, as a target for anti-cancer therapy. Front. Mol. Biosci. 5, 26 (2018). · DOI
  28. Li, Y. & Prives, C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 26, 2220–2225 (2007). · DOI · Paper page
  29. Salama, M. et al. Fam83F induces p53 stabilisation and promotes its activity. Cell Death Differ. 26, 2125–2138 (2019). · DOI
  30. Dixit, U., Liu, Z., Pandey, A. K., Kothari, R. & Pandey, V. N. Fuse binding protein antagonizes the transcription activity of tumor suppressor protein p53. BMC Cancer 14, 925 (2014). · DOI
  31. Malkomes, P. et al. Transglutaminase 2 promotes tumorigenicity of colon cancer cells by inactivation of the tumor suppressor p53. Oncogene 40, 4352–4367 (2021). · DOI
  32. Stelzl, U. et al. A human protein-protein interaction network: a resource for annotating the proteome. Cell 122, 957–968 (2005). · DOI · Paper page
  33. Schaefer-Ramadan, S., Aleksic, J., Al-Thani, N. M. & Malek, J. A. Novel protein contact points among TP53 and minichromosome maintenance complex proteins 2, 3, and 5. Cancer Med. 11, 4989–5000 (2022). · DOI
  34. Qiu, W. G. et al. Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer. NPJ Breast Cancer 3, 1 (2017). · DOI
  35. DaFonseca, C. J., Shu, F. & Zhang, J. J. Identification of two residues in MCM5 critical for the assembly of MCM complexes and Stat1-mediated transcription activation in response to IFN-gamma. Proc. Natl Acad. Sci. USA 98, 3034–3039 (2001). · DOI
  36. Ferguson, R. L., Pascreau, G. & Maller, J. L. The cyclin A centrosomal localization sequence recruits MCM5 and Orc1 to regulate centrosome reduplication. J. Cell. Sci. 123, 2743–2749 (2010). · DOI
  37. Ferguson, R. L. & Maller, J. L. Cyclin E-dependent localization of MCM5 regulates centrosome duplication. J. Cell. Sci. 121, 3224–3232 (2008). · DOI
  38. McKinley, K. L. & Cheeseman, I. M. Large-scale analysis of CRISPR/Cas9 cell-cycle knockouts reveals the diversity of p53-dependent responses to cell-cycle defects. Dev. Cell 40, 405–420.e402 (2017). · DOI · Paper page
  39. Bakhoum, S. F. & Cantley, L. C. The multifaceted role of chromosomal instability in cancer and its microenvironment. Cell 174, 1347–1360 (2018). · DOI · Paper page
  40. Tanaka, N. et al. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1. Oncogene 37, 1279–1292 (2018). · DOI
  41. Dittmer, D. et al. Gain of function mutations in p53. Nat. Genet. 4, 42–46 (1993). · DOI · Paper page
  42. Halevy, O., Michalovitz, D. & Oren, M. Different tumor-derived p53 mutants exhibit distinct biological activities. Science 250, 113–116 (1990). · DOI · Paper page
  43. Hong, C., Tijhuis, A. E. & Foijer, F. The cGAS paradox: contrasting roles for cGAS-STING pathway in chromosomal instability. Cells 8, 1228 (2019). · DOI
  44. Hou, Y. et al. Non-canonical NF-kappaB antagonizes STING sensor-mediated DNA sensing in radiotherapy. Immunity 49, 490–503.e494 (2018). · DOI · Paper page
  45. Jin, J. et al. Noncanonical NF-kappaB pathway controls the production of type I interferons in antiviral innate immunity. Immunity 40, 342–354 (2014). · DOI
  46. Li, J. et al. Non-cell-autonomous cancer progression from chromosomal instability. Nature 620, 1080–1088 (2023). · DOI · Paper page
  47. Del Poggetto, E. et al. Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. Science 373, eabj0486 (2021). · DOI · Paper page
  48. Martin, T. D. et al. The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation. Science 373, 1327–1335 (2021). · DOI
  49. Cooks, T. et al. Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 23, 634–646 (2013). · DOI · Paper page
  50. Rahnamoun, H. et al. Mutant p53 shapes the enhancer landscape of cancer cells in response to chronic immune signaling. Nat. Commun. 8, 754 (2017). · DOI
  51. Schneider, G. et al. Cross talk between stimulated NF-kappaB and the tumor suppressor p53. Oncogene 29, 2795–2806 (2010). · DOI · Paper page
  52. Weisz, L. et al. Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res. 67, 2396–2401 (2007). · DOI · Paper page
  53. Di Minin, G. et al. Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP. Mol. Cell 56, 617–629 (2014). · DOI · Paper page
  54. Vaughan, C. A. et al. p53 mutants induce transcription of NF-kappaB2 in H1299 cells through CBP and STAT binding on the NF-kappaB2 promoter and gain of function activity. Arch. Biochem. Biophys. 518, 79–88 (2012). · DOI
  55. Scian, M. J. et al. Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol. Cell. Biol.25, 10097–10110 (2005). · DOI
  56. Sun, S. C. Non-canonical NF-kappaB signaling pathway. Cell Res. 21, 71–85 (2011). · DOI · Paper page
  57. Polotskaia, A. et al. Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4. Proc. Natl Acad. Sci. USA 112, E1220–1229 (2015). · DOI · Paper page
  58. Kogan, A. A. et al. Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia. Proc. Natl Acad. Sci. USA 119, e2123227119 (2022). · DOI
  59. Wilkie, M. D. et al. TP53 mutations in head and neck cancer cells determine the Warburg phenotypic switch creating metabolic vulnerabilities and therapeutic opportunities for stratified therapies. Cancer Lett. 478, 107–121 (2020). · DOI
  60. Zhao, M. et al. Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin. Cancer Res. 17, 7248–7264 (2011). · DOI · Paper page
  61. Neskey, D. M. et al. Evolutionary action score of TP53 identifies high-risk mutations associated with decreased survival and increased distant metastases in head and neck cancer. Cancer Res. 75, 1527–1536 (2015). · DOI · Paper page
  62. Zhou, G. et al. Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation. Mol. Cell 54, 960–974 (2014). · DOI · Paper page
  63. Mendez, J. & Stillman, B. Chromatin association of human origin recognition complex, cdc6, and minichromosome maintenance proteins during the cell cycle: assembly of prereplication complexes in late mitosis. Mol. Cell Biol. 20, 8602–8612 (2000). · DOI · Paper page
  64. Risom, T. et al. Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma. Cell 185, 299–310.e218 (2022). · DOI · Paper page
  65. Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105–1111 (2009). · DOI · Paper page
  66. Li, H. et al. The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078–2079 (2009). · DOI · Paper page
  67. Anders, S., Pyl, P. T. & Huber, W. HTSeq–a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166–169 (2015). · DOI · Paper page
  68. Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015). · DOI · Paper page
  69. Liu, J. et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173, 400–416.e411 (2018). · DOI · Paper page
  70. Broad-Institute-TCGA-Genome-Data-Analysis-Center. Mutation Analysis (MutSig 2CV v3.1), <https://doi.org/10.7908/C18C9VM5> (2016). · doi:10.7908/c18c9vm5
  71. Ellrott, K. et al. Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines. Cell Syst. 6, 271–281.e277 (2018). · DOI · Paper page
  72. Mayakonda, A., Lin, D. C., Assenov, Y., Plass, C. & Koeffler, H. P. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28, 1747–1756 (2018). · DOI · Paper page
  73. Broad-Institute-TCGA-Genome-Data-Analysis-Center. Firehose stddata__2016_01_28 run, <https://doi.org/10.7908/C11G0KM9> (2016). · DOI
  74. Campbell, J. D. et al. Genomic, pathway network, and immunologic features distinguishing squamous carcinomas. Cell Rep. 23, 194–212.e196 (2018). · DOI · Paper page
  75. Mak, M. P. et al. A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition. Clin. Cancer Res. 22, 609–620 (2016). · DOI · Paper page

Cited by

See all 65

Metadata

Authors
Zhao, M., Wang, T., Gleber-Netto, F. O., Chen, Z., McGrail, D. J., Gomez, J. A., Ju, W., Gadhikar, M. A., Ma, W., Shen, L., Wang, Q., Tang, X., Pathak, S., Raso, M. G., Burks, J. K., Lin, S.-Y., Wang, J., Multani, A. S., Pickering, C. R., Chen, J., Myers, J. N., & Zhou, G.
Venue
Nature Communications
Published
2024-01-02
Volume
15
Issue
1
ISSN
2041-1723
Cited by
65
References
22
Language
en
Licence
Funders
U.S. Department of Health & Human Services | National Institutes of Health (R01-DE014613, R01-DE030875)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response. https://app.cochat.ai/papers/10.1038/s41467-023-44239-2
The paper
Zhao, M., Wang, T., Gleber-Netto, F. O., Chen, Z., McGrail, D. J., Gomez, J. A., Ju, W., Gadhikar, M. A., Ma, W., Shen, L., Wang, Q., Tang, X., Pathak, S., Raso, M. G., Burks, J. K., Lin, S.-Y., Wang, J., Multani, A. S., Pickering, C. R., . . . Zhou, G. (2024). Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response. Nature Communications. https://doi.org/10.1038/s41467-023-44239-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.